Inactive Instrument

Melinta Therapeutics, Inc.

Equities

Biotechnology & Medical Research

Melinta Therapeutics Appoints Eugene Sun as Chief Executive Officer and Member of the Board of Directors

April 19, 2016 at 09:00 am EDT

The Board of Directors of Melinta Therapeutics announced that Eugene Sun, M.D. has been appointed Melinta's Chief Executive Officer and member of the Board of Directors, making permanent the role he has filled in an interim capacity since September 2015. Sun most worked recently as Corporate Vice President, Global Pharmaceutical Clinical Development.

Latest news about Melinta Therapeutics, Inc.

Venatorx Pharmaceuticals and Melinta Therapeutics Provide Update on Status of U.S. New Drug Application for Cefepime-Taniborbactam	Feb. 23	CI
New England Journal of Medicine Publishes Positive Results of Cefepime-Taniborbactam from Phase 3 CERTAIN-1 Study of Patients with Complicated Urinary Tract Infection	Feb. 20	CI
Melinta Therapeutics, Llc and Cidara Therapeutics, Inc. Announce Publication of Pooled Data from Phase 3 Pivotal Restore Trial & Phase 2 Strategic Trial of Rezafungin for Injection in the Lancet Id	Dec. 05	CI
Melinta Therapeutics Announces Expanded Reimbursement and Access for REZZAYO (Rezafungin for Injection)	23-10-02	CI
Melinta Therapeutics Partners with BARDA to Advance Two FDA-Approved Antibiotics for Use in Pediatric Patients, and for Use Against Biothreat Pathogens	23-07-10	CI
Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO (Rezafungin for Injection) for the Treatment of Candidemia and Invasive Candidiasis	23-03-22	CI
Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis	23-01-25	CI
Cidara Therapeutics, Inc. and Melinta Therapeutics, LLC Announce Publication of Data from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in The Lancet	22-11-28	CI
Melinta Therapeutics, Inc. Acquires U.S. Rights to TOPROL-XL® (Metoprolol Succinate) from New American Therapeutics, Inc	22-04-06	CI
Melinta Therapeutics Announces Two Key Milestones Expanding Reimbursement and Access for KIMYRSA™	21-09-20	CI
Melinta Therapeutics Announces Commercial Availability of KIMYRSA™ (oritavancin)	21-07-07	CI
Melinta Therapeutics Announces Appointment of Jisoo Park as Head of Business Development, M&A and Strategy	21-07-06	CI
Melinta Therapeutics, Inc. Announces Appointment of Susan Blum as Chief Financial Officer. Effective July 1, 2021	21-06-29	CI
Melinta Therapeutics, LLC Appoints John Harlow as Chief Commercial Officer	21-03-29	CI
Melinta Therapeutics, LLC Announces FDA Approval of KIMYRSA™ (oritavancin) for the Treatment of Adult Patients with Acute Bacterial Skin and Skin Structure Infections	21-03-15	CI
Melinta Therapeutics, LLC Appoints Kristen Allgor as Chief Human Resources Officer	20-11-16	CI
Melinta Therapeutics Announces Executive Changes	20-08-03	CI
Melinta Therapeutics Announces CEO Changes	20-08-03	CI
Melinta Therapeutics, Inc. cancelled the acquisition of Tetraphase Pharmaceuticals, Inc..	20-06-23	CI
Melinta Therapeutics, Inc. made a proposal to acquire Tetraphase Pharmaceuticals, Inc. for $13.1 million.	20-05-14	CI
Melinta Therapeutics, Inc. Emerged from Bankruptcy	20-04-20	CI
Second Modified First Amended Reorganization Plan Approved for Melinta Therapeutics, Inc.	20-04-11	CI
First Amended Disclosure Statement Approved for Melinta Therapeutics, Inc.	20-02-25	CI
First Amended Reorganization Plan and Disclosure Statement Filed by Melinta Therapeutics, Inc.	20-02-19	CI
Bidding Procedure Approved for Melinta Therapeutics, Inc.	20-02-11	CI

Chart Melinta Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Melinta Therapeutics Inc is a United States-based commercial-stage antibiotics company. The Company's products include Vabomere, Orbactiv, Minocin for injection, and Baxdela. Baxdela is indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Vabomere is indicated for the treatment of patients over 18 years of age and older with complicated urinary tract infections (cUTI), including pyelonephritis. Orbactiv is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSIs). Minocin for injection is indicated for the treatment of infections due to susceptible isolates of designated microorganisms, including Acinetobacter species bacteria.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+8.63%	115B
REGENERON PHARMACEUTICALS, INC.	+13.17%	107B
BIONTECH SE	-12.76%	22.31B
ARGENX SE	-3.99%	21.6B
BEIGENE, LTD.	-7.19%	18.23B
WUXI APPTEC CO., LTD.	-39.93%	17.62B
NEUROCRINE BIOSCIENCES, INC.	+6.67%	14.26B
SAREPTA THERAPEUTICS, INC.	+33.90%	12.37B
LEGEND BIOTECH CORPORATION	-28.60%	8.28B

Bio Therapeutic Drugs